IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure ProSense Cryoablation Evaluated in Treatment for Breast Cancer - Endovascular Today

April 22, 2025—IceCure Medical Ltd. announced findings from three investigator-initiated studies of the company’s ProSense system for the cryoablation treatment of breast cancer. The data were delivered in two scientific sessions and one poster presentation at ECIO 2025, the European Conference on Interventional Oncology held April 13-16 in Rotterdam, the Netherlands. First, Sophie M. Wooldrik, MD, presented “Review of the indications and result…

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific sessionIndependent studies of ProSense® featured in scientific sessions and abstracts including data from the THERMAC trial stating 95% of patients said they would choose thermal ablation…